Skip to main content


Fig. 5 | Virology Journal

Fig. 5

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Fig. 5

Comparison of HLA-A*0201/EBV-BMLF1-GLC-specific CD8+ T cells in patients with and without EBV-related diseases. The percentages of HLA-A*0201/BMLF1-GLC-specific CTLs at + 30 days after haplo-HSCT in patients with and without EBV-related diseases are shown. EBV-CTL percentage data were available for 5 patients at + 90 days in the HLA-A*0201 group, but none of these subjects suffered from EBV-related diseases. Thus, we did not analyze the difference of HLA-A*0201/EBV-BMLF1-GLC-specific CTLs at + 90 days

Back to article page